
Addressing Mcl-1 by Fragment-Based Methods – A Retrospective



Dr Anders Friberg, Nuvisan ICB GmbH

Anders focused his graduate studies on protein structure elucidation and protein-ligand interaction studies, mainly by NMR (Technical University Munich, Germany). During his postdoctoral stay in the lab of Steve Fesik at Vanderbilt University (Nashville, TN) his interest moved to drug discovery in general and fragment-based methods in particular. Today, at Nuvisan ICB (previously Bayer Pharma Research, Berlin), he is a senior scientist in the Structural Biology group within the Lead Discovery department. Here, he supports (external) drug discovery projects with structural data during lead optimization, as well as early projects with starting points identified by NMR-based fragment screening.